Trobix Bio Company Profile

Background

Founded in 2018 and headquartered in Netanya, Israel, Trobix Bio is a biotechnology company specializing in the development of precision microbiome oncology therapeutics. The company's mission is to mitigate the adverse gastrointestinal side effects associated with cancer treatments, thereby enhancing patient quality of life and enabling the completion of optimal oncology treatment regimens. By leveraging advanced technologies such as CRISPR, phage therapy, and synthetic biology, Trobix Bio aims to address significant unmet needs in oncology supportive care.

Key Strategic Focus

Trobix Bio's strategic focus centers on the development of orally administered therapeutics designed to modulate the gut microbiome, thereby reducing severe side effects caused by cancer treatments. The company's core objectives include:

TBX201: An orally available capsule intended to reduce the incidence and severity of severe diarrhea caused by irinotecan, a first-line chemotherapy drug used in treating various metastatic cancers.

TBX301: An orally available capsule aimed at decreasing the incidence and severity of colitis in patients undergoing treatment with immune checkpoint inhibitors (ICIs), such as CTLA-4, PD-1, or PD-L1 inhibitors.

These products target primary markets where gastrointestinal side effects from oncology treatments present substantial challenges to patient care and treatment adherence.

Financials and Funding

Trobix Bio has successfully secured funding to advance its research and development initiatives:

Series A Funding (July 2020): The company closed a $3 million Series A funding round led by Chartered Opus, aimed at advancing its antimicrobial resistance platform technology and pre-clinical development of its lead product, TBX101.

Series A Extension (March 2023): An additional $3 million equity investment was secured from Chartered Group to further develop Trobix Bio's products and proprietary platform technology addressing gastrointestinal side effects of oncology treatments.

These funds are allocated towards advancing the company's product pipeline and enhancing its technological platforms.

Pipeline Development

Trobix Bio's pipeline includes several key candidates:

TBX201: Designed to mitigate severe diarrhea induced by irinotecan chemotherapy.

TBX301: Aimed at reducing colitis in patients treated with immune checkpoint inhibitors.

TBX101: Targets patients carrying gut antimicrobial-resistant bacteria, with the goal of restoring an antibiotic-sensitive gut microbiome.

These candidates are in various stages of preclinical development, with ongoing efforts to progress them through clinical trials.

Technological Platform and Innovation

Trobix Bio's proprietary TBX™ platform integrates computational biology, synthetic biology, and phage engineering to develop therapeutics that precisely reprogram targeted microbiome bacteria. This approach ensures robust and durable therapeutic effects by:

Proprietary Technologies: Utilizing engineered phages to deliver specific DNA cargos to bacteria, effectively modulating the microbiome.

Scientific Methodologies: Employing CRISPR technology and synthetic biology to achieve high precision in bacterial gene editing.

This innovative platform positions Trobix Bio at the forefront of microbiome-based therapeutic development.

Leadership Team

Trobix Bio's leadership comprises experienced professionals with extensive backgrounds in biotechnology and business development:

Dr. Adi Elkeles, Ph.D.: Founder, Chief Executive Officer, and Chairman. Dr. Elkeles has nearly two decades of experience in leading biomedical entrepreneurship and innovation, with a proven track record in advancing technologies from preclinical stages to market approval.

Udi Qimron: Chief Technology Officer and Scientific Advisor.

Chanan Morris: Chief Financial Officer.

The board of directors includes notable members such as Eyal Agmoni (Chartered Investment Managers), Eitan Dekel, and Keren Primor-Cohen (CEO of Ramot at Tel Aviv University).

Competitor Profile

Market Insights and Dynamics

The precision microbiome oncology therapeutics market is emerging, with increasing recognition of the microbiome's role in cancer treatment outcomes. The market is characterized by:

Growth Potential: Rising demand for therapies that mitigate side effects of cancer treatments.

Industry Trends: Integration of microbiome modulation in oncology care to enhance treatment efficacy and patient quality of life.

Competitor Analysis

Key competitors in this space include:

OncoHost: Focuses on personalized oncology through proteomic analysis to predict patient responses to treatments.

NephroDI Therapeutics: Develops treatments for nephrogenic diabetes insipidus, indirectly competing in the broader field of therapeutic innovation.

MindMed: Specializes in psychedelic-inspired therapies for mental health, representing competition in the innovative biotech sector.

These companies, while differing in specific focus areas, contribute to the competitive landscape of innovative therapeutic development.

Strategic Collaborations and Partnerships

Trobix Bio has established significant partnerships to bolster its market position and innovation capacity:

Chartered Group: A global private investment group that has provided substantial funding to support Trobix Bio's development initiatives.

Ramot at Tel Aviv University: Collaboration with the university's technology transfer office, facilitating research and development efforts.

These partnerships enhance Trobix Bio's capabilities in advancing its therapeutic pipeline.

Operational Insights

In the competitive landscape of microbiome-based therapeutics, Trobix Bio distinguishes itself through:

Proprietary TBX™ Platform: A unique integration of computational biology, synthetic biology, and phage engineering.

Focus on Oncology Supportive Care: Targeting significant unmet needs in reducing side effects of cancer treatments.

Strategic Funding: Securing investments that enable sustained research and development efforts.

These factors position Trobix Bio as a leader in the development of precision microbiome therapeutics.

Strategic Opportunities and Future Directions

Looking ahead, Trobix Bio aims to:

Advance Clinical Trials: Progress pipeline candidates through clinical development stages.

Expand Therapeutic Applications: Explore additional indications where microbiome modulation can provide therapeutic benefits.

Strengthen Partnerships: Forge new collaborations to enhance research capabilities and market reach.

By leveraging its technological strengths and strategic partnerships, Trobix Bio is well-positioned to achieve its future objectives in the biotechnology sector.